Zuclopenthixol LA-Sulpiride

From Psychiatrienet
Revision as of 15:24, 26 August 2009 by Verena (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Zuclopenthixol
long acting
Type Antipsychotic
Group Thioxanthenes
links
PubChem 5311507
PubMed Zuclopenthixol
Kompas (Dutch) Zuclopenthixol
Wikipedia Zuclopenthixol
Sulpiride
Type Antipsychotic
Group Atypical AP
links
PubChem 5355
PubMed Sulpiride
Kompas (Dutch) Sulpiride
Wikipedia Sulpiride

Switch medication from Zuclopenthixol_LA to Sulpiride.

Nietinrijdenbord.png Stop Zuclopenthixol_LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Sulpiride
  • Week 1-3: approx. 25% of target dose
  • Week 4-6: approx. 50% of target dose
  • Week 7-9: approx. 75% of target dose
  • Week 10: target dose
Letopbord.png Cave
  • During this switch ECG monitoring is required because of possible QT-interval prolongation[1][2]
Infobord.png More information
StopDepotStartOral.jpg
Nietinrijdenbord.png — Zuclopenthixol_LA
Eenrichtingbord.png — Sulpiride


  1. SPC Sertindole (Dutch)
  2. SPC Sertindole
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.